Phase II trial of idarubicin in patients with advanced lymphoma

Gillies, H.; Liang, Raymond; Rogers, H. J.; Harper, Peter; Parapia, L. A.; Cox, Geoffrey; Johnson, S.

doi:10.1007/bf00262782

Cited by 21 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Idarubicin has been of special interest for the treatment of high-grade NHL in elderly patients because of the following reasons: (i) When applied in an oral form, the substance has demonstrated efficacy in both chemonaive (response rates 31-86% of cases [115,116]) as well as in pretreated patients (response rates 17-26% [117,118]). …”

Section: Pirarubicin (4)-o-tetrahydropyranyldoxorubicin Thpadriamycimentioning

confidence: 99%

Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly

Greil

1998

Oncology

View full text Add to dashboard Cite

Lymphomas belong to the class of malignant diseases with the fastest increasing incidence. High-grade non-Hodgkin’s lymphomas (NHL) display a peak of incidence in the age group above 65. In the last few years, age has been recognized as a major risk factor for overall survival of high-grade NHL patients, and numerous attempts have been made to analyze the contribution of factors to the age-related worsening of prognosis in this disease, e.g. the biology of the disease on the one hand, and age-specific comorbidity or degree of cytotoxicity, reluctance in diagnosis and treatment and socioeconomic factors on the other. Furthermore, age-adapted treatment protocols have been designed and tested for their practicability and efficacy in the elderly. Very recently, large randomized prospective clinical trials have been carried out which support the idea that treatment with a curative intent is warranted even in the very elderly and that a successful attempt to cure requires the use of full-dose anthracycline-containing regimens closely similar to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). In addition, progress has been made in systematically defining maximally tolerated doses of the cytotoxic drugs and in specifically testing anthracyclines with reduced cardiotoxicity with an efficacy similar to that of doxorubicin, and further in investigating the advantage of applying hematopoietic growth factors and/or cardioprotective drugs in this older population. In limited stages of disease, three cycles of CHOP chemotherapy followed by involved field irradiation may be superior to radiotherapy and prolonged chemotherapy and may produce highly satisfying cure rates.

show abstract

Section: Pirarubicin (4)-o-tetrahydropyranyldoxorubicin Thpadriamycimentioning

confidence: 99%

Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly

Greil

1998

Oncology

View full text Add to dashboard Cite

show abstract

“…A depletion of sodium and calcium within the crust with respect to the pristine glass and a more or less marked enrichment for aluminum, iron and manganese is generally reported for decay products of potash-lime and soda-lime glass [4,9,19,20,22,24,28]; less agreement arises for potassium and magnesium, since either depletion [4,9] or enrichment [20,28] were reported for both of them, or even a pronounced enrichment in potassium in the crust, without mention of the magnesium behavior [22]. A thorough work on the decay of archaeological soda-lime medieval glass further suggests that sodium may be more easily leached out of the glass, or less easily incorporated in the decay phases, with respect to potassium [24].…”

Section: Composition Of the Crust With Respect To Pristine Glass Compmentioning

confidence: 99%

Morphological and chemical characterization of weathering products on buried Sasanian glass from central Iraq

Gulmini

Pace

Ivaldi

et al. 2009

Journal of Non-Crystalline Solids

View full text Add to dashboard Cite

“…The drug is approved for the treatment of acute leukemia, and has significant activity in non-Hodgkin's lymphoma. 22,23 In fact, a small phase III trial demonstrated that substitution of idarubicin (10 mg/m 2 ) for doxorubicin (50 mg/m 2 ) in combination with cyclophosphamide, vincristine, and prednisone resulted in an equivalent complete response (CR) rate with less cardiac toxicity in patients with intermediate-grade nonHodgkin's lymphoma. 24 Furthermore, Minderman et al 25 have reported that idarubicin exhibited greater schedule dependence favoring protracted exposure than doxorubicin in a K562 human leukemia cell line.…”

mentioning

confidence: 99%

Phase II Trial of Infusional Cyclophosphamide, Idarubicin, and Etoposide in Poor Prognosis Non-Hodgkin’s Lymphoma

Salman

Perez

Sparano

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The purpose of this study was to determine the complete response (CR) rate, failure-free survival (FFS), and overall survival (OS) of patients with poor-prognosis intermediate-grade non-Hodgkin's lymphoma (NHL) after treatment with cyclophosphamide, idarubicin, and etoposide given as a continuous intravenous infusion (CIVI) over 96 hours (infusional CIE), including patients with relapsed/refractory disease and patients with no prior therapy but at least two poor-risk features by the age-adjusted International Prognostic Index. Forty-two patients with previously untreated NHL (N = 24) or relapsed/refractory (N = 18) NHL received cyclophosphamide (200 mg/m2/d), idarubicin (2.5-3.0 mg/m2/d) and etoposide (60 mg/m2/d) given by a 96-hour CIVI every 3 weeks for a maximum of 8 cycles. All patients also received granulocyte-colony-stimulating factor. CR occurred in 10 of 24 patients (42%; 95% confidence intervals [CI] 22%, 62%) treated with CIE as first-line therapy, and in 3 of 18 patients (17%; 95% CI 20%, 32%) treated with CIE as second-line or greater therapy. One-year FFS and OS were 42% and 64%, respectively, in patients with no prior therapy, and 17% and 56% in patients with prior therapy. Severe (grade III) or life-threatening (grade IV) toxicity included leukopenia (59%), anemia (61%), thrombocytopenia (31%), and infection (10%). Two patients (4%) died due to treatment related infectious complications. It is unlikely that infusional CIE produces a CR rate more than about 60% in poor-risk patients with intermediate-grade NHL when used as first-line therapy, or more than about 30% in patients receiving the regimen as second-line therapy. Substitution of idarubicin for doxorubicin in this setting, therefore, is not associated with an improved response rate.

show abstract

Phase II trial of idarubicin in patients with advanced lymphoma

Cited by 21 publications

References 5 publications

Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly

Prognosis and Management Strategies of Lymphatic Neoplasias in the Elderly

Morphological and chemical characterization of weathering products on buried Sasanian glass from central Iraq

Phase II Trial of Infusional Cyclophosphamide, Idarubicin, and Etoposide in Poor Prognosis Non-Hodgkin’s Lymphoma

Contact Info

Product

Resources

About